Jove
Visualize
Contact Us

Related Experiment Videos

Interaction of bothrojaracin with prothrombin.

R B Zingali1, M L Bianconi, R Q Monteiro

  • 1Departamento de Bioquímica Médica/ICB/CCS, Bloco H-2o Andar-Ilha do Fundao, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-590, Brazil. lzingali@bioqmed.ufrj.br

Haemostasis
|March 23, 2002
PubMed
Summary

Bothrojaracin (BJC), a protein from snake venom, inhibits blood clotting by targeting both thrombin and its precursor, prothrombin. This dual action offers potential for new anticoagulant therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2021
Same author

<sup>1</sup>H, <sup>15</sup>N and <sup>13</sup>C resonance assignments of Ixolaris, a tissue factor pathway inhibitor from the tick salivary gland.

Biomolecular NMR assignments·2017
Same author

Recombinant expression of Ixolaris, a Kunitz-type inhibitor from the tick salivary gland, for NMR studies.

Protein expression and purification·2017
Same author

A biophysical characterization of the interaction of a hepatitis C virus membranotropic peptide with micelles.

Biochimica et biophysica acta·2016
Same author

Structural basis for the interaction of human β-defensin 6 and its putative chemokine receptor CCR2 and breast cancer microvesicles.

Journal of molecular biology·2013
Same author

The tick-derived inhibitor Ixolaris prevents tissue factor signaling on tumor cells.

Journal of thrombosis and haemostasis : JTH·2012
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Biochemistry
  • Venom research
  • Hemostasis and thrombosis

Background:

  • Bothrojaracin (BJC) is a 27-kD protein isolated from Bothrops jararaca venom.
  • BJC binds to alpha-thrombin via anion-binding exosites I and II with high affinity (K(D) = 0.7 nM).

Purpose of the Study:

  • To investigate the interaction of BJC with human prothrombin, specifically its zymogen form.
  • To elucidate the mechanisms by which BJC exerts its anticoagulant effects.

Main Methods:

  • Biochemical assays to determine binding affinities (K(D)) between BJC and human prothrombin/alpha-thrombin.
  • Analysis of BJC's effect on prothrombin activation by various factors (e.g., Oxyuranus scutellatus venom, factor Xa/Va, phospholipids).

Main Results:

Related Experiment Videos

  • BJC forms a 1:1 Ca(2+)-independent noncovalent complex with human prothrombin's proexosite I (K(D) = 75 nM).
  • BJC inhibits prothrombin activation by Oxyuranus scutellatus venom and significantly reduces factor Xa/Va-mediated prothrombin activation, especially in the presence of phospholipids.
  • These findings suggest BJC specifically inhibits prothrombin's interaction with factor Va.

Conclusions:

  • BJC possesses dual anticoagulant mechanisms: inhibiting alpha-thrombin activity via exosites I and II, and blocking prothrombin activation through interaction with proexosite I.
  • BJC's specific inhibition of the prothrombin-factor Va interaction is a key aspect of its anticoagulant function.